secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001193125-25-249348
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology receives $30M milestone from Kyowa Kirin for first patient dosed in Phase 3 ziftomenib trial
--------------------------------------------------------------------------------

- $30M milestone payment triggered by first patient dosed in KOMET-017 Phase 3 registrational trials.
- Trials evaluate ziftomenib in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.
- KOMET-017 consists of two global, randomized, double-blind, placebo-controlled Phase 3 studies.
- Payment received under Collaboration and License Agreement with Kyowa Kirin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525249348/0001193125-25-249348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525249348/d939392d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-249348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer